Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

28.45USD
14 Aug 2018
Change (% chg)

$0.70 (+2.52%)
Prev Close
$27.75
Open
$28.45
Day's High
$29.05
Day's Low
$27.95
Volume
86,242
Avg. Vol
146,784
52-wk High
$36.25
52-wk Low
$16.55

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $1,189.59
Shares Outstanding(Mil.): 46.65
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.94 -- --
ROI: -3.56 1.78 14.61
ROE: -6.31 3.28 16.33

UPDATE 2-Acorda loses bid for U.S. court order halting generic Ampyra sales

July 25 A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

25 Jul 2018

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

25 Jul 2018

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

02 May 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

19 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

02 Apr 2018

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

26 Mar 2018

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

14 Mar 2018

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - ‍ UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD​

28 Feb 2018

BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija

* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

20 Feb 2018

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

15 Feb 2018

Earnings vs. Estimates